Parcopa (carbidopa-levodopa orally disintegrating tablets) by Woelfel, Joseph A.
University of the Pacific
Scholarly Commons
School of Pharmacy and Health Sciences Faculty
Articles
Thomas J. Long School of Pharmacy and Health
Sciences
11-1-2004
Parcopa (carbidopa-levodopa orally disintegrating
tablets)
Joseph A. Woelfel
University of the Pacific, jwoelfel@pacific.edu
Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy and Health Sciences at Scholarly Commons. It has
been accepted for inclusion in School of Pharmacy and Health Sciences Faculty Articles by an authorized administrator of Scholarly Commons. For
more information, please contact mgibney@pacific.edu.
Recommended Citation
Woelfel, J. A. (2004). Parcopa (carbidopa-levodopa orally disintegrating tablets). Pharmacist’s Letter & Prescriber’s Letter, 20(11), 1–2.
https://scholarlycommons.pacific.edu/phs-facarticles/68
 
More. . . 
Copyright © 2004 by Therapeutic Research Center 
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone:  209-472-2240 ~ Fax:  209-472-2249 








−This Detail-Document accompanies the related article published in− 
PHARMACIST’S LETTER / PRESCRIBER’S LETTER 
November 2004 ~ Volume 20 ~ Number 201113 
 
 
Parcopa (Carbidopa-Levodopa Orally Disintegrating Tablets) 
Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
 
Background 
In August 2004, Schwarz Pharma received the 
FDA’s approval of Parcopa (carbidopa-levodopa 
orally disintegrating tablets) for treating 
Parkinson’s disease.  It is similar to immediate 
release Sinemet and the generic equivalents but 
differs in its unique dissolving formulation.  The 
new RapiTab dosage form dissolves rapidly on 
the tongue without the need for water.  This is 
especially useful for Parkinson’s patients who 
often have difficulty swallowing. 
In a 2003 national survey, it was found that 
40% of adults experienced difficulty in 
swallowing pills.  Of these adults, 26% reported 




Parcopa is available in three strengths of the 
carbidopa-levodopa combination: 10 mg-100 mg, 
25 mg-100 mg, and 25 mg-250 mg.  It is not rated 
as a therapeutic equivalent to immediate-release 
Sinemet or Sinemet generic equivalents.2  It is a 
therapeutic alternative for patients with 
swallowing difficulties.  
The Parcopa is mint-flavored and dissolves 
rapidly on the tongue.  It can be swallowed with 
or without water.   
Parcopa carries the same indications, 
contraindications, warnings, precautions, adverse 
reactions, drug interactions, and dosage 
recommendations as with Sinemet.  Like Sinemet, 
it is an immediate-release formulation designed to 
begin release of ingredients within 30 minutes.3,4   
Parcopa can be packaged in conventional 
prescription bottles or in blister packs without 
concern for durability as is the case with some 











Phenylketonuric patients should be informed 
that Parcopa contains phenylalanine.  The orally-
disintegrating 10-100 mg and the 25-100 mg 
tablets contain 3.4 mg per tablet.  The 25-250 mg 
tablets contain 8.4 mg of phenylalanine per tablet.  
Patients should be advised to remove tablets 
from the bottle just prior to use.  They should 
have dry hands and immediately place the tablet 
on their tongue. 
 
Commentary 
The average wholesale cost for Parcopa is 
approximately 40% more than for brand name 
Sinemet.5  This difference in cost may be offset by 
improved patient compliance and quality of life in 




Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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